GlassScriptPhysician profile
Kasra Adham
NPI 1053630285
$5,698.40
in general payments reported to CMS, 2019-2025
27 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $53.32 · 2021: $354 · 2022: $808 · 2023: $1,212 · 2024: $392 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.37 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $957.34 | 2019-2023 | Exalt Model D |
| Pentax of America, INC. | $556.70 | 2023 | Video Colonoscope |
| Janssen Biotech, INC. | $512.35 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $476.86 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $444.22 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $311.37 | 2019-2022 | |
| Genzyme Corporation | $276.91 | 2024-2025 | |
| Allergan, INC. | $226.31 | 2019 | |
| Apollo Endosurgery US INC | $212.92 | 2019 | |
| Celgene Corporation | $211.14 | 2023-2024 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $195.67 | 2022 | |
| Pfizer INC. | $183.35 | 2023-2025 | |
| Madrigal Pharmaceuticals | $171.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $152.01 | 2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.02 | 2024-2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $127.13 | 2019-2025 | |
| Dilon Technologies, INC. | $99.99 | 2025 | Hemoblast Bellows |
| Lilly USA, LLC | $68.85 | 2025 | Omvoh |
| Stryker Corporation | $65.12 | 2025 | Neptune |
| Medtronic, INC. | $52.79 | 2025 | Gi Genius |
| Phathom Pharmaceuticals, INC. | $44.13 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $43.92 | 2023-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $38.90 | 2023-2024 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $37.58 | 2025 | Dupixent |
| Celltrion USA INC. | $37.20 | 2024 | Zymfentra |
| Qol Medical, LLC | $29.28 | 2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $24.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasra Adham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.